3.54k followers • 19 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Intuitive Surgical, Inc.
Boston Scientific Corporation
Smith & Nephew plc
Globus Medical, Inc.
Cardiovascular Systems, Inc.
K2M Group Holdings, Inc.
Mazor Robotics Ltd.
All an investor needs to do is to buy shares of public companies that have a competitive advantage -- and that, as a result, can continue generating growing revenue and earnings for decades -- and hold these shares for a long time. Today, we'll look at two healthcare stocks that sport a healthy moat, and explore why both of these stocks are worth adding to your portfolio. Vertex Pharma is a biotech company that has one of the most compelling competitive advantages any business can have: The company holds a monopoly in the market for drugs that treat the underlying causes of cystic fibrosis (CF), a genetic condition that causes damage to internal organs such as the lungs.
When you think "medical robots," what name jumps to mind first? When it comes to pure-play medical robotics companies that make robots to assist surgeons in performing their surgeries, Intuitive Surgical is the one to beat (rivals Mazor Robotics and Mako Surgical having already been gobbled up and subsumed into larger med-tech companies). As it turns out, when the Pentagon thinks about investing in surgical robots, Intuitive Surgical is the one they call, too.
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
DLA Piper represented advised NuVasive, Inc. (NASDAQ: NUVA), a San Diego-based medical device company that creates and distributes products for surgical treatment of spine disorders, in its offering of US$400 million aggregate principal amount of 1.00% convertible senior notes due 2023. NuVasive also granted to the initial purchasers of the convertible notes a 13-day option to purchase up to an additional US$50 million principal amount of the notes.
Medtronic plc (MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
NuVasive, Inc. (NASDAQ: NUVA) announced today that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes"), pursuant to the exercise in full of the initial purchasers' option to purchase such additional notes (the "Option Notes") in connection with the previously announced Convertible Notes offering that closed on June 1, 2020.
ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?
DUBLIN, June 03, 2020 -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 41st Annual Global.
Upgrades * Morgan Stanley upgraded the stock for Cloudera Inc (NYSE: CLDR) from Equal-Weight to Overweight. The stock has a 52-week-high of $12.22 and a 52-week-low of $4.76. Cloudera's stock last closed at $11.24 per share. * For Hologic Inc (NASDAQ: HOLX), Raymond James upgraded the stock from Market Perform to Outperform. For the second quarter, Hologic had an EPS of $0.57, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $55.25 and a 52-week-low of $26.49. Hologic's stock last closed at $52.71 per share. * Piper Sandler upgraded the stock for Kontoor Brands Inc (NYSE: KTB) from Neutral to Overweight. In the first quarter, Kontoor Brands earned $0.27. The stock has a 52-week-high of $43.23 and a 52-week-low of $12.90. Kontoor Brands's stock last closed at $17.03 per share. * DA Davidson changed the rating for Zoom Video Communications Inc (NASDAQ: ZM) from Neutral to Buy. For the first quarter, Zoom Video Communications had an EPS of $0.20, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $212.69 and a 52-week-low of $60.97. Zoom Video Communications's stock last closed at $208.08 per share. * For Zoom Video Communications Inc (NASDAQ: ZM), RBC Capital upgraded the stock from Sector Perform to Outperform. For the first quarter, Zoom Video Communications had an EPS of $0.20, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $212.69 and a 52-week-low of $60.97. Zoom Video Communications's stock last closed at $208.08 per share. Initiations * Cowen & Co. initiated coverage on Deckers Outdoor Corp (NYSE: DECK) with an Outperform rating. The price target for Deckers Outdoor is set at $220.00. For the fourth quarter, Deckers Outdoor had an EPS of $0.57, compared to year-ago quarter EPS of $0.85. The stock has a 52-week-high of $204.10 and a 52-week-low of $78.70. Deckers Outdoor's stock last closed at $204.00 per share. * With a rating of Buy, Brookline Capital initiated coverage on Assertio Holdings Inc (NASDAQ: ASRT). The price target is set at $3.50 for Assertio Holdings. Assertio Holdings earned $0.10 in the first quarter, compared to $0.23 in the year-ago quarter. The stock has a 52-week-high of $3.63 and a 52-week-low of $0.55. Assertio Holdings's stock last closed at $0.99 per share. * For Allegion PLC (NYSE: ALLE), William Blair initiated coverage, by setting the current rating at Market Perform. Allegion earned $1.04 in the first quarter, compared to $0.88 in the year-ago quarter. The stock has a 52-week-high of $139.24 and a 52-week-low of $77.37. Allegion's stock last closed at $100.03 per share.See more from Benzinga * Recap: Vera Bradley Q1 Earnings * Recap: American Eagle Outfitters Q1 Earnings * Pyxis Tankers: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announced the publication of new clinical evidence further validating the exceptional performance of its proprietary OXINIUM - Oxidized Zirconium - on XLPE (highly cross-linked polyethylene) for total hip arthroplasty (THA). The publication in The Journal of Bone and Joint Surgery Open Access analyses data from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) and concludes that THA procedures using OXINIUM on XLPE were associated with the lowest risk of revision of all bearing combinations for any reason beyond 10 years.1
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020, at 3:20 p.m. CDT.
Medtronic's (NYSE: MDT) most recently reported quarter, the fourth quarter of its fiscal year 2019, failed to impress investors. In addition to its dismal performance during the fourth quarter, Medtronic shares have performed worse than the broader market. Despite these less-than-flattering metrics, there are several good reasons to consider buying shares of the medical devices company; here are three.
Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.
BRAMPTON, ON , June 2, 2020 /CNW/ - Medtronic Canada ULC, a subsidiary of Medtronic plc (MDT) – one of the world's largest medical technology, services, and solutions companies – announced today that it has been named on the 2020 list of Best Workplaces for mental wellness. Medtronic Canada ULC received this honour after a thorough and independent analysis conducted by Great Place to Work®. "Ensuring our employees' safety and wellbeing – both physical and mental – has always been paramount," said Neil Fraser , president of Medtronic Canada.
Natera, Inc. (NTRA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is excited to announce the publication of a health economic study in Wound Management and Prevention, which states that the use of PICO™ Single Use Negative Pressure Wound Therapy System (sNPWT) is estimated to be highly cost effective when compared with traditional NPWT (tNPWT), and may therefore provide opportunity to reduce the economic burden of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).1
While panic-selling can certainly be unnerving if you're a short-term trader, it's always been an opportunity to buy into great companies at a discount if you're a long-term investor. Throughout the 33-calendar-day decline in the broader market in February and March, I took the opportunity to add quite a few new companies to my investment portfolio. The single greatest thing about Intuitive Surgical is the fact that the company's operating margins are built to improve over time.